The association of tumor necrosis factor superfamily 13 with recurrence of immunoglobulin A nephropathy in living related kidney transplantation

• Published in: BMC nephrology Vol. 20; no. 1; pp. 33 - 7
• Main Authors: Jo, Hyung Ah, Han, Seung Seok, Lee, Sunhwa, Kim, Joo Young, Yang, Seung Hee, Lee, Hajeong, Yang, Jae Seok, Lee, Jung Pyo, Joo, Kwon Wook, Lim, Chun Soo, Kim, Yon Su, Ahn, Curie, Han, Jin Suk, Kim, Dong Ki
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 31.01.2019; BioMed Central; BMC
• Subjects: Adult; Antigens; B cells; Biopsy; Care and treatment; Demographic aspects; Development and progression; Family; Female; Follow-Up Studies; Galactose; Glomerulonephritis, IGA - blood; Glomerulonephritis, IGA - surgery; Graft Survival; Health aspects; Humans; Iga glomerulonephritis; IgA nephropathy; Immune system; Immunoglobulin A; Immunoglobulins; Kidney diseases; Kidney Transplantation; Kidney transplants; Laboratories; Ligands; Living Donors; Male; Middle Aged; Necrosis; Nephrology; Organ transplantation; Patient outcomes; Patients; Prognosis; Recurrence; Recurrence (Disease); Risk factors; Rodents; Surgery; Transplants & implants; Treatment Outcome; Tumor necrosis factor; Tumor Necrosis Factor Ligand Superfamily Member 13 - blood; Tumor necrosis factor superfamily 13; Tumor necrosis factor-TNF; Tumors; South Korea; United States > US; Tumor necrosis factor superfamily 13; Recurrence; IgA nephropathy
• ISSN: 1471-2369; 1471-2369
• DOI: 10.1186/s12882-019-1222-4

An increasing amount of evidence has demonstrated an association between an increase in the level of tumor necrosis factor superfamily 13 (TNFSF13) and immunoglobulin A nephropathy (IgAN) progression. We aimed to evaluate if the level of pre-transplant serum TNFSF13 is predictive of IgAN recurrence after kidney transplantation. This analysis was based on the clinical and laboratory data of 69 patients with IgAN who underwent first kidney transplantation with no evidence of mesangial IgA deposits in zero-time transplantation biopsy. We measured pre-transplant serum TNFSF13, total IgA, and galactose-deficient IgA1 levels. The recurrence rate of IgAN over a median follow-up duration of 5.1 years was 15.9% (11/69 patients), with a mean time to the first recurrence of 1.7 years. The high pre-transplant TNFSF13 level was associated with IgAN recurrence after kidney transplantation among patients who received a graft from a living related donor. This study highlights association of TNFSF13 levels in recurrent IgAN patients who undergo living related donor transplantation. Further research is needed to clarify mechanisms by which TNFSF13 affects the recurrence of IgA nephropathy.